Recombinase Polymerase Amplification Coupled with CRISPR-Cas12a for Rapid Detection of Ciprofloxacin-Resistance Mutations in Clinical Urinary Isolates

Bacterial infections of the urinary tract are among the most common ailments treated in hospitals and clinics around the world. While many cases clear up on their own or with simple care, others require antibiotics to prevent the infection from spreading. For decades, doctors have relied on a class of drugs called fluoroquinolones to treat these infections because they work well and are easy to take. However, bacteria are clever and adaptable; over time, many have learned to ignore these drugs, rendering them useless. When a patient is infected with a resistant strain, the standard treatment fails, and the infection can become dangerous. The current way to find out if a specific bacterium is resistant involves growing the germ in a lab dish and watching how it reacts to the drug. This process is reliable but slow, often taking one to three days to produce a result. In that time, patients may receive the wrong medication, or the infection may worsen. Scientists have long sought a faster way to detect resistance, one that looks directly at the genetic code of the bacteria to find the specific changes that make them immune to treatment.

A team of researchers has developed a new method that combines two powerful biological tools to solve this problem. The first tool is a technique that acts like a molecular photocopier, able to make millions of copies of a specific piece of bacterial DNA in a single step, without needing the complex heating and cooling cycles of traditional machines. The second tool is a molecular scissors system, originally discovered as a bacterial immune defense, which can be programmed to hunt for a very specific sequence of genetic letters. When this system finds its target, it snaps open and cuts a glowing chemical tag, creating a signal that can be seen with the naked eye under a simple ultraviolet light. By linking these two tools together, the researchers created a test that can identify the genetic mutations responsible for ciprofloxacin resistance in just one hour.

The researchers tested this new system on 137 real-world bacterial samples collected from patients with urinary tract infections. These samples came from three of the most common types of bacteria that cause these infections: Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Before testing their new method, the team first mapped out the genetic landscape of these bacteria using a gold-standard sequencing technique. They found that resistance in these bacteria usually comes from tiny changes in specific genes that control how the bacteria build their internal machinery. In E. coli, the most common resistance pattern involved two specific changes working together, while in the other two species, the changes were slightly different. This confirmed that a single test design would not work for all bacteria; the test had to be tailored to the specific genetic signature of each species.

The team then designed seven unique genetic "guides" to hunt for these specific mutations. Each guide was programmed to recognize only the mutated version of the gene that causes resistance, ignoring the normal, healthy version. When they ran their new test on the 137 samples, the results were striking. For the E. coli samples, the test successfully identified every single one of the 18 bacteria that were known to be resistant to the drug, but only when the researchers combined multiple guides into a single panel to look for the various possible resistance mutations. It did this by looking for any of the known resistance mutations and flagging them. The test was also highly accurate for Proteus mirabilis, catching 95 percent of the resistant cases. For Klebsiella pneumoniae, the test found 58 percent of the resistant cases. The researchers noted that the missed cases in this group were likely due to a different type of resistance mechanism that does not involve the specific genes they were looking for, meaning the test is not perfect for every single type of resistance but is highly effective for the most common genetic causes.

One of the most important findings was how the test handled bacteria that were not yet fully resistant. The test sometimes flagged bacteria that had started to develop a resistance mutation but had not yet become fully resistant to the drug. The researchers explained that this is not a mistake, but rather a feature. In the case of E. coli, the test flagged five bacteria that were phenotypically susceptible to the drug; however, genetic sequencing confirmed that these five isolates carried a specific "first-step" mutation (S83L) that is the initial stage of developing resistance. While these bacteria were not yet resistant in the lab, they possessed the genetic change that precedes full resistance. The researchers noted that this is not a false positive in the traditional sense, but rather the detection of a "pre-resistant" genotype. This could be incredibly useful for doctors, allowing them to switch treatments early before the infection becomes harder to treat. Crucially, the test never flagged a bacterium as resistant if it lacked the specific genetic mutation associated with resistance; every positive signal corresponded to a genuine genetic change, even if that change had not yet resulted in full drug resistance.

The entire process is remarkably simple and fast. Unlike traditional genetic testing, which requires expensive, bulky machines that cycle through different temperatures, this new method works at a single, constant warm temperature. The researchers could extract the DNA from the bacteria by simply boiling them in water, mix the sample with the reagents, and wait. Within an hour, they could look at the tube under a UV light. If the bacteria were resistant, the liquid would glow. If they were not, it would remain dark. This simplicity means the test could eventually be used in smaller clinics or resource-limited settings where complex equipment is unavailable.

The study demonstrates that it is possible to move beyond slow, culture-based testing and directly detect the genetic roots of antibiotic resistance in a fraction of the time. By combining a rapid DNA copying method with a precise genetic search tool, the researchers have created a system that is both fast and accurate for the most common types of urinary tract infections. While the test does not catch every single possible way bacteria can become resistant, it successfully identifies the vast majority of the most common genetic causes. This approach offers a promising path toward faster, smarter treatment decisions, helping to ensure that patients receive the right antibiotic sooner and slowing the spread of drug-resistant superbugs.